![Cogent Biosciences, Inc. logo](/logos/COGT.webp)
Cogent Biosciences, Inc.
NASDAQ:COGT
Overview | Financials
Company Name | Cogent Biosciences, Inc. |
Symbol | COGT |
Currency | USD |
Price | 10.47 |
Market Cap | 1,145,941,500 |
Dividend Yield | 0% |
52-week-range | 3.67 - 12.485 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Andrew R. Robbins M.B.A. |
Website | https://www.cogentbio.com |
An error occurred while fetching data.
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD